Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $38
Portfolio Pulse from jenniferd'souza@benzinga.com
Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on ACADIA Pharmaceuticals but lowers the price target from $39 to $38.
August 04, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ACADIA Pharmaceuticals' price target has been lowered from $39 to $38 by Canaccord Genuity, though the 'Buy' rating is maintained.
The news directly pertains to ACADIA Pharmaceuticals. While the lowering of the price target might be seen as a negative, the maintenance of the 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100